UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers and clinical trials in ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.120979, Article 120979

Genge, Angela

2023

Volltextzugriff (PDF)

2997 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: interim analysis of RAISE-XT

BMJ neurology open, 2024-08, Vol.6 (Suppl 1), p.A13-A13

2024

Volltextzugriff (PDF)

Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study

Neurology. Genetics, 2021-12, Vol.7 (6), p.e623-e623

2021

Volltextzugriff (PDF)

Aesthetic Temporalities Today: Present, Presentness, Re-Presentation

1, 2020

Volltextzugriff (PDF)

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Art History and Fetishism Abroad: Global Shiftings in Media and Methods

1, 2014

Volltextzugriff (PDF)

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Chest, 2011-10, Vol.140 (4), p.687A-687A

2011

Volltextzugriff (PDF)

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

BMC musculoskeletal disorders, 2013-05, Vol.14 (S2), p.P1-P1, Article P1

Genge, Angela

2013

Volltextzugriff (PDF)

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Journal of the neurological sciences, 2023-12, Vol.455, p.121088, Article 121088

2023

Volltextzugriff (PDF)

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.122737, Article 122737

2023

Volltextzugriff (PDF)

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Journal of the neurological sciences, 2023-12, Vol.455, p.122738, Article 122738

2023

Volltextzugriff (PDF)

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Journal of the neurological sciences, 2023-12, Vol.455, p.121718, Article 121718

2023

Volltextzugriff (PDF)

Use of Rituxan in Autoimmune Neuromuscular Diseases and Outcomes in 3 Key Disease Groups (P02.194)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Treatment of Severe AIDPN with Methylprednisolone, a Series of 8 Cases (P01.130)

Neurology, 2013-02, Vol.80 (7_supplement)

2013

Volltextzugriff (PDF)

Amyotrophic Lateral Sclerosis (ALS) Genetic Testing: Current Landscape and Potential Needs (2691)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

24-Week Results From Phase 3 Study MT-1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (P1-13.001)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

RAISE-XT: interim analysis of an open-label extension study of zilucoplan in patients with myasthenia gravis

Journal of neurology, neurosurgery and psychiatry, 2023-11, Vol.94 (Suppl 1), p.A81-A82

2023

Volltextzugriff (PDF)

Spinraza in Adults with Spinal Muscular Atrophy (SAS) – 14 month results (S33.010)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Longitudinal bulbar and respiratory declines in Amyotrophic Lateral Sclerosis (ALS) (4786)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS) (2474)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaAmyotrophic Lateral Sclerosis

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(144)

Publikationsform

Buchkapitel
(121)
Artikel
(65)
Bücher
(2)
Reviews
(1)

Sprache

Englisch
(189)

Erscheinungsjahr

n.n

Thema

Arts & Humanities
(15)
History Of Art / Art & Design Styles
(7)
Social & Cultural History
(7)
Theory Of Art
(6)
Cultural Studies
(5)
Humans
(3)
Male
(3)
Middle Aged
(3)
Myasthenia Gravis
(3)
Activities Of Daily Living
(2)
Aged
(2)
Clinical Trials
(2)
Culture
(2)
Female
(2)
Fine Arts
(2)
Genetics
(2)
History
(2)
Adaptation, Psychological
(1)
Adaptive Trial Design
(1)
Adult
(1)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

Biomarkers and clinical trials in ALS

2997 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: interim analysis of RAISE-XT

Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study

Aesthetic Temporalities Today: Present, Presentness, Re-Presentation

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

Art History and Fetishism Abroad: Global Shiftings in Media and Methods

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Use of Rituxan in Autoimmune Neuromuscular Diseases and Outcomes in 3 Key Disease Groups (P02.194)

Treatment of Severe AIDPN with Methylprednisolone, a Series of 8 Cases (P01.130)

Amyotrophic Lateral Sclerosis (ALS) Genetic Testing: Current Landscape and Potential Needs (2691)

24-Week Results From Phase 3 Study MT-1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (P1-13.001)

RAISE-XT: interim analysis of an open-label extension study of zilucoplan in patients with myasthenia gravis

Spinraza in Adults with Spinal Muscular Atrophy (SAS) – 14 month results (S33.010)

Longitudinal bulbar and respiratory declines in Amyotrophic Lateral Sclerosis (ALS) (4786)

The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS) (2474)

Aktive Filter

Suchergebnisse filtern